Graham Walmsley Buys Shares of OLMA
Graham Walmsley acquired 29,500 shares of OLMA on June 18, 2026.
Key Points
- Graham Walmsley purchased 29,500 shares of OLMA on June 18, 2026.
- On Wednesday, OLMA shares traded near $10.00.
- Several analysts maintain buy ratings with price targets up to $62.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Graham Walmsley, an insider at OLMA, purchased 29,500 shares of the company on June 18, 2026. This transaction wasn't part of a pre-planned trading scheme.
Insider Buying and Selling at Olema Pharmaceuticals, Inc.
Alongside Graham Walmsley, other insiders including Sandra Horning, Yi Larson, Andrew Rappaport, Gorjan Hrustanovic, and Ian Clark each bought 29,500 shares of OLMA on the same day. These transactions were also not conducted under pre-planned trading arrangements.
Other Institutional Activity in OLMA
Several institutional investors adjusted their holdings in OLMA recently. FMR LLC significantly increased its stake, adding 5,363,753 shares to hold a total of 10,386,845 shares valued at about $154.9 million, marking a 106.8% increase. Paradigm Biocapital Advisors LP also grew its position by 476,404 shares, ending with 8,020,576 shares worth $119.6 million, a 6.3% increase. Meanwhile, Bain Capital Life Sciences Investors, LLC reduced its holdings by 1,035,403 shares, now holding 7,473,238 shares valued at $111.4 million, which is a 12.2% decrease. Janus Henderson Group PLC and BlackRock, Inc. both increased their stakes slightly, with Janus Henderson adding 398,294 shares and BlackRock adding 88,875 shares.
Olema Pharmaceuticals, Inc. Stock Up 2.5%
On Wednesday, OLMA's shares traded near $10.00. The stock's recent performance includes a 52-week low and high, with significant institutional interest reflected in the recent trades.
$OLMA stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Several analysts have maintained a positive outlook on OLMA. On May 13, 2026, Guggenheim maintained its buy rating with a price target of $35.00. Jefferies assumes a buy rating with a $40.00 target as of March 19, 2026. JP Morgan also maintained a buy rating with a higher target of $58.00 on March 18, 2026. Other firms like Goldman Sachs, Citigroup, and HC Wainwright & Co. have set targets ranging from $27.00 to $62.00, all maintaining buy ratings.
Bottom Line
Graham Walmsley's purchase of OLMA shares signals confidence in the company's future. The recent insider buying, along with significant institutional activity, suggests that many see potential in OLMA. Analysts are also optimistic, with several maintaining high price targets. Investors often track such insider and institutional moves as they can provide insights into the company's prospects.
Get Olema Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OLMA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.